Moderna and Merck Move Personalized Melanoma Vaccine Toward Filing

Phase 3 data showed intismeran plus Keytruda reduced the risk of melanoma recurrence or death versus Keytruda alone. A filing is planned, but approval timing, manufacturing and profit sharing still shape the investment case.
Moderna and Merck are moving their personalized cancer therapy intismeran toward regulatory filing after a Phase 3 melanoma trial met its main goals. The development gives Moderna its most important late-stage evidence outside respiratory vaccines and offers Merck a possible way to extend growth around Keytruda.
The INTerpath-001 study enrolled 1,137 patients with completely resected stage IIB through IV melanoma. Patients received intismeran plus Keytruda or Keytruda alone after surgery. At the prespecified analysis, the combination reduced the risk of recurrence or death by 42%, corresponding to a hazard ratio of 0.58. The two-year recurrence-free survival rate was 82.2% with the combination and 70.0% with Keytruda alone.
The distant-metastasis result also favored the combination. Two-year distant metastasis-free survival was 88.5% versus 80.2%. Overall survival remains under evaluation, so the trial does not yet establish a survival benefit. Treatment-related adverse events occurred in 95.8% of combination patients and 90.0% of the Keytruda-only group. Grade 3 through 5 treatment-related events were 14.2% and 13.4%, respectively.
Intismeran is manufactured from information taken from each patient's tumor and normal DNA. Moderna uses the tumor's mutation profile to select up to 34 neoantigens and encode them in an individualized messenger RNA treatment. That mechanism is scientifically differentiated, but it also makes manufacturing speed, consistency and cost central to commercialization.
Moderna said on November 6 that it and Merck planned to submit the therapy for regulatory review in 2026, with management hoping for approval in 2027. The companies share profits equally. Every intismeran patient in this regimen also receives Keytruda, which gives Merck a strategic benefit beyond its share of the new therapy's economics.
The program is not yet a commercial product. Regulators must review efficacy, safety and the individualized manufacturing process, while overall survival data are still immature. Investors should distinguish the 42% relative risk reduction from an absolute cure rate and from the earlier Phase 2 result, which used a different follow-up period.
For Moderna, the filing would test whether its platform can produce a repeatable oncology business. For Merck, it could strengthen the post-2028 Keytruda portfolio, but it will not materially change near-term earnings before approval and launch. The next decisive evidence is the regulatory submission, followed by review of manufacturing readiness and the evolving survival data.
Continue your MRK research
Image references: · Moderna (Public domain simple text and geometry; trademarks reserved)
Frequently asked questions
What is "Moderna and Merck Move Personalized Melanoma Vaccine Toward Filing" about?
Phase 3 intismeran data support a planned filing, while survival data, personalized manufacturing and regulatory review remain key risks.
Which stocks and assets does this article cover?
This article relates to MRK.
What is the market context?
Moderna and Merck are moving their personalized cancer therapy intismeran toward regulatory filing after a Phase 3 melanoma trial met its main goals. The development gives Moderna its most important late-stage evidence outside respiratory vaccines and offers Merck a possible way to extend growth around Keytruda. The INTerpath-001 study enrolled 1,137 patients with completely resected stage IIB…
When was this article published?
It was published on 13 / 11 / 2026 by Be The Investor Research.



